Details

Autor(en) / Beteiligte

• Pasau, Thomas
• Wauters, Els
• Wauters, Isabelle
• Duplaquet, Fabrice
• Pirard, Lionel
• Pop-Stanciu, Claudia
• D’Haene, Nicky
• Dupont, Michael
• Vander Borght, Thierry
• Rondelet, Benoît
• Ocak, Sebahat

Titel

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

Ist Teil von

• Frontiers in oncology, 2022-11, Vol.12

Ort / Verlag

Frontiers Media S.A

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have improved the prognosis of advanced-stage non-small cell lung cancer (NSCLC) with ALK rearrangement, but resistance mechanisms limit their efficacy. We describe the case of a 63-year-old man with a stage cIVA ALK -rearranged lung adenocarcinoma who developed a BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib, a second-generation ALK TKI. He was treated with an association of BRAF and MEK inhibitors but death occurred two months after treatment initiation in a context of tumor progression and toxicity. Based on this first report of BRAF A598-T599insV mutation occurring in lung cancer, we discuss resistance mechanisms to ALK TKIs, implications of BRAF mutation in NSCLC, and BRAF A598-T599insV mutation in other cancers.